Outside big pharma, life remains tough for listed developers
A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.
Crunch time for the Spac space
This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.
Biopharma’s stock market winners of 2021 revealed
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
Diabetes device makers lead the smaller medtechs
Insulin pumps and glucose sensors flew off the shelves, whereas liquid biopsy developers both soared and sank.
Big beasts drive biopharma valuations higher in 2021
A handful of huge success stories mask disappointing performances elsewhere, with small caps and Asian pharma firms feeling the pain.
A bad year to be an American medtech
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
